Korean drugmaker HanAll Biopharma said Tuesday it has appointed Christopher Slavinsky, former Coherus BioSciences chief business and legal officer, as the chief business development and legal officer aiming to bolster global expansion efforts.
Slavinsky has over 25 years of experience in legal and business development roles across major pharmaceutical companies and emerging biotechnology firms. His track record includes leading and closing over $20 billion in strategic transactions, including transformational M&A and integration, asset purchases and asset divestitures.
Prior to the appointment, he worked for Coherus BioSciences, where he led Coherus’ $65 million all-stock acquisition of Surface Oncology, an immunotherapy developer.
He also played a critical role in Coherus’ commercialization of Yusimry, a biosimilar of blockbuster rheumatoid arthritis treatment Humira, through a partnership with Cost Plus Drugs, an online pharmacy platform. Slavinsky held leadership positions at Pharmacosmos Therapeutics, Prometheus Biosciences, Takeda and Pfizer.
“I am excited to join HanAll and contribute my expertise to pioneer cutting-edge therapies targeting unmet medical needs,” Slavinsky said in a press release.
“I am honored to join a talented global team and look forward to collaborating with academic and industry partners in service of patients in need.”
HanAll Biopharma CEO Sean Jeong said, “Chris brings a wealth of expertise to HanAll with his proven track record at leading biopharmaceutical companies and deep knowledge in legal and business strategy.”
“His experience in driving transformative initiatives and navigating complex regulatory landscapes will be instrumental as we continue to innovate and expand our presence in the industry,” the CEO added.
Slavinsky holds a degree in biochemistry from the State University of New York at Stony Brook, a master’s in biochemistry and molecular 커뮤니티 biology from Thomas Jefferson University and a juris doctor from the University of Washington School of Law.
HanAll Biopharma has been operating a portfolio of pharmaceutical products in the therapeutic areas of endocrine, circulatory and urologic diseases for over 50 years. It recently focused on novel medicines in immunology, oncology, neurology and ophthalmology.
Its leading pipeline assets include autoimmune diseases treatment batoclimab, which is being developed in Phase 3 and Phase 2 trials around the world.